<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000652</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 176</org_study_id>
    <secondary_id>NCI 91 C-09</secondary_id>
    <nct_id>NCT00000652</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To assess the safety and tolerance of the combination of zidovudine (AZT) and didanosine&#xD;
      (ddI) in children with HIV infection.&#xD;
&#xD;
      New approaches to using available agents may provide increased or improved treatment options&#xD;
      for AIDS. Combination therapy is expected to play a major role in improving survival and&#xD;
      quality of life for HIV-infected individuals. AZT and ddI are two agents that have been most&#xD;
      extensively evaluated and for which the evidence for antiretroviral effectiveness is&#xD;
      strongest.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New approaches to using available agents may provide increased or improved treatment options&#xD;
      for AIDS. Combination therapy is expected to play a major role in improving survival and&#xD;
      quality of life for HIV-infected individuals. AZT and ddI are two agents that have been most&#xD;
      extensively evaluated and for which the evidence for antiretroviral effectiveness is&#xD;
      strongest.&#xD;
&#xD;
      Patients take AZT and ddI on an empty stomach; ddI is taken 2 minutes after taking antacid.&#xD;
      Part A patients receive AZT plus ddI each at ranging doses. Patients in part B may receive a&#xD;
      higher dose of ddI than patients in part A. The first patients enrolled are given the lowest&#xD;
      dose. Subsequent patients receive increasingly higher doses until a dose limiting toxicity&#xD;
      occurs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">November 1995</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>85</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Corticosteroids for treatment of lymphocytic interstitial pneumonitis.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Intravenous hyperalimentation.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  P-2 class symptomatic HIV infection as defined by CDC OR who are asymptomatic but&#xD;
             whose total CD4 cell count is &lt; 500 cells/mm3.&#xD;
&#xD;
          -  Freedom from significant active opportunistic or other infection requiring specific&#xD;
             therapy.&#xD;
&#xD;
        Part B patients:&#xD;
&#xD;
          -  Prior treatment with zidovudine (AZT) that was discontinued because of hematologic&#xD;
             toxicity.&#xD;
&#xD;
          -  Availability of a parent or legal guardian who is sufficiently reliable to give&#xD;
             informed consent and follow necessary study procedures including administration of&#xD;
             medications and return for follow-up visits.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Critically ill, clinically unstable, or receiving drug therapy for an opportunistic or&#xD;
             other infection.&#xD;
&#xD;
          -  History of acute or chronic pancreatitis.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Critically ill, clinically unstable, or receiving drug therapy for an opportunistic or&#xD;
             other infection.&#xD;
&#xD;
          -  History of acute or chronic pancreatitis.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral or other antiviral agent within 14 days of entry into study.&#xD;
&#xD;
          -  Immunomodulating agents, cytolytic chemotherapeutic agents, corticosteroids within 30&#xD;
             days (except for lymphocytic interstitial pneumonitis).&#xD;
&#xD;
        Part A patients:&#xD;
&#xD;
          -  Zidovudine (AZT) or didanosine (ddI).&#xD;
&#xD;
        Part B patients:&#xD;
&#xD;
          -  Didanosine (ddI).&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy within 30 days.&#xD;
&#xD;
          -  Intravenous immunoglobulin preparations within 14 days of entry into study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PA Pizzo</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>RN Husson</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hosp of Los Angeles/UCLA Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900276016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mueller BU, Pizzo PA, Farley M, Husson RN, Goldsmith J, Kovacs A, Woods L, Ono J, Church JA, Brouwers P, et al. Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. J Pediatr. 1994 Jul;125(1):142-6. doi: 10.1016/s0022-3476(94)70141-5.</citation>
    <PMID>8021765</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 31, 2012</last_update_submitted>
  <last_update_submitted_qc>October 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2012</last_update_posted>
  <keyword>Didanosine</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

